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Interleukin  1  (IL-1), 1 formerly  lymphocyte activating  factor,  was originally 
described in  1972 by Gery et al.  (1) as a  product of human  monocytes capable 
of stimulating the proliferation of murine thymocytes. Subsequent studies have 
shown that monocyte-macrophages from other species also produce a polypeptide 
mediator  capable of stimulating  murine  thymocyte proliferation  (2,  3).  These 
and  subsequent studies suggest that  IL-1  may be an  important  signal  in T  (4) 
and  B  lymphocyte activation  (5).  Furthermore,  in addition  to its immunologic 
properties, IL-1 may be an important mediator in chronic inflammation. This is 
based  on  studies  showing  that  IL-1  or  molecules  similar  to  IL-1  function  as 
endogenous pyrogens (6), stimulate the production of collagenase by fibroblasts 
(7) and by rheumatoid synovial cells (8), and stimulate the release of acute phase 
reactants by liver (9).  Molecules very similar or identical  to IL-1  also stimulate 
fibroblast proliferation  and  therefore  may contribute  to the  fibrosis often ob- 
served in chronic inflammatory diseases (10,  1 1). Although  the results of these 
studies are provocative and suggest that IL-1  may be an important  mediator in 
a  variety  of physiologic  and  pathophysiologic  processes,  the  conclusions  are 
tentative  because partially  purified  IL-1  was used in  these  studies.  Moreover, 
some of the IL-1  preparations  were prepared in the presence of phorbol esters 
(12)  or  carrier  ampholytes  (13),  each  of which  has  been  demonstrated  to  be 
active in diverse in vitro biological assay systems (14-16). 
Some progress has been made in the purification and biochemical characteri- 
zation  of human  IL-1  since  its  discovery  in  1972.  Studies  show  that  it  is  a 
polypeptide having an approximate molecular weight of 15,000 (17) and a major 
isoelectric point  (pI)  of 6.8  (13).  Minor  charged  species possessing isoelectric 
points of 5.2,  5.4, and  6.0 have also been described (13), though  the basis for 
this  charge  heterogeneity  is  unclear.  Detailed  biochemical  characterization  of 
human  IL-1  has  been  hampered,  however,  by  the  lack  of a  rapid,  efficient 
purification  procedure.  Although  highly enriched  preparations  of human  IL-1 
have  been  prepared  using  either  ultrafiltration  and  isoelectric  focusing  (IEF) 
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techniques (18) or a polyspecific rabbit antiserum containing antibodies to IL-1 
(19),  there  is  not  yet  convincing  data  that  these  procedures  are  capable  of 
producing homogeneously pure material suitable for amino acid analysis, spectral 
analysis, or ligand binding studies.  Although  murine  IL-1  has been purified to 
homogeneity (12), there is evidence that human  IL-1  differs significantly from 
murine  IL-1  with  respect to its biochemical and  antigenic  properties.  Human 
IL-1 has a much higher pI than does murine IL-1 (4.9-5.1) and is inactivated by 
a-chymotrypsin  (17),  whereas  murine  IL-1  is  resistant  to  inactivation  by  a- 
chymotrypsin (20).  Moreover, a  heteroiogous antiserum  raised against  murine 
IL-1 cross-reacted with human IL-1 only weakly (21). 
The purification of human  IL-1 has been difficult because (a) there is no cell 
line capable of producing relatively large amounts of this material under serum- 
free  culture  conditions  (22),  and  because  (b)  most  conventional  purification 
procedures  yield  poor  recovery  of activity  (12,  13,  17,  18).  In  this  study, 
peripheral  blood  mononuclear  cells  were  obtained  in  large  quantities  from 
normal donors by leukopheresis and cultured under serum-free conditions in the 
presence of purified phytohemagglutinin  in order to produce culture superna- 
tants containing a high specific activity of IL-1. IL-1  was purified from concen- 
trated  culture  supernatant  using  a  combination  of anion  exchange  and  size 
exclusion  high  performance  liquid  chromatography  (HPLC).  The  separations 
performed by HPLC anion  exchange  chromatography  were novel in that  iso- 
cratic,  instead  of gradient,  conditions  were  employed  (see  reference  23  for 
review). The culture conditions and purification procedure presented here yield 
a  highly  purified  preparation  of human  IL-1  consisting  of a  single  charged 
species, and free of contaminating phorbol esters and carrier ampholytes. 
Materials and Methods 
Mononuclear  Cell  Cultures.  Peripheral  blood  mononuclear  cells  were  obtained  by 
leukopheresis of normal volunteers using an IBM 2997 blood cell separator. The resulting 
cell suspension  (1 X 10 I° mononuclear cells in 200 ml) was supplemented with 300 U of 
heparin and diluted with an equal volume of culture medium consisting of RPMI-1640 
that contained 20 mM Hepes, 4 mM  glutamine,  100  U]ml penicillin,  and  100 /~g/ml 
streptomycin.  The  mononuclear  cell  fraction  was  then  obtained  using  Ficoll  Paque 
(Pharmacia,  Piscataway,  N  J) discontinuous density gradients.  The  interface cells were 
diluted with an equal volume of culture medium and centrifuged at 4°C for 10 min at 
250 g. The cell pellets were resuspended in 50 ml of culture medium and counted. After 
centrifugation, the cells were resuspended in culture medium with or without 1% fetal 
calf serum [No. 309, Gibco, Grand Island, NY] at a concentration of 5 x  106/ml. 100-ml 
volumes of cell suspension  were placed in upright or horizontal  75-cm  2 flasks (Coming 
No. 25110, Corning, NY), supplemented with purified phytohemagglutinin (Burroughs 
Wellcome, Research Triangle, NC) at a final concentration of 1 t~g]ml, and incubated for 
4 d at  37°C in a  humidified atmosphere of 5%  CO~]air.  In preliminary  experiments, 
aliquots of culture supernatants were carefully removed at daily intervals during the 4-d 
culture period in order to measure thymocyte proliferation activity and IL-2 activity as 
detailed below. 
Supernatant  Preparation.  The culture supernatants were clarified by centrifugation at 
3,000 g for 30 rain at 4 ° C, supplemented with polyethylene glycol to minimize nonspecific 
adsorption (tool wt ---- 6,000;  30 /~g/ml, final concentration) and sodium azide  (0.04%, 
final concentration), and then filtered through a 0.45-micron Metricel filter (Giison, Ann 
Arbor, MI). For preparative purposes, the supernatant was then concentrated approxi- 
mately  20-fold by a  Pellicon  cassette  ultrafiltration  device (Millipore,  Bedford,  MA) 774  PURIFICATION OF  NORMAL  HUMAN  IL-1 
equipped with 0.5  ft  ~ of a  PT membrane having a  nominal molecular weight exclusion 
limit of 10,000.  The retentate was subsequently concentrated an additional  50-fold by 
means of a  stirred cell  ultrafiltration  device (Amicon, Danvers, MA) equipped with an 
Amicon YM-10 membrane. The crude concentrate was dialyzed against 5  mM NaiPO4 
(pH 7.25) and filtered through a Millipore 0.22-#m Millex-GV filter. 
Anion Exchange HPLC.  200-#1 aliquots of the crude concentrate (~6 mg protein) were 
chromatographed isocratically on a  preparative Synchropak AX300  column (250  X  10 
mm; Synchrom, Linden, IN) equilibrated in 5 mM NaiPO4 buffer, pH 7.25, at a flow rate 
of 3 ml/min. This and subsequent chromatography steps in the purification protocol were 
performed at ambient temperature by a  programmable Hewlett-Packard  1084B  liquid 
chromatograph equipped  with  injector,  peak integrator,  variable wavelength detector, 
and effluent collection device. The active fractions from several consecutive runs were 
pooled and concentrated -200-fold using an Amicon model 8  MC ultrafiitration device 
equipped  with  a  YM-10  membrane.  Aliquots  (150  ~i)  of this  concentrate  were  then 
chromatographed as above on  an analytical size  (250  x  4.1  mm) Synchropak AX300 
column at a flow rate of 1 ml/min. Fractions were collected in tubes containing polyeth- 
ylene glycol (final concentration  100 #g/ml) and the active fractions were concentrated as 
above. After 10 consecutive isocratic runs, each of the AX300 columns was washed with 
a gradient of increasing ionic strength (5-500 mM Na~ PO4, pH 7.25) in order to remove 
bound proteins. 
Size Exclusion High Performance Liquid Chromatography.  Aliquots (150 #1) of the con- 
centrated material obtained after rechromatography on Synchropak AX300  were chro- 
matographed on a 600 x  7.5 mm TSK-G 2000 SW HPLC size exclusion column (LKB, 
Gaithersburg, MD) equilibrated in  100 mM Na~PO4 buffer, pH 6.95, at a flow rate of 1 
ml/min. The column was calibrated with the following molecular weight standards: BSA, 
67,000;  ovalbumin, 43,000;  soybean trypsin inhibitor,  21,500;  ribonuclease A,  13,700; 
and aprotinin, 6,500. 
Analytical SDS Gradient PAGE.  Gradient gels (10-30% T  with 2.6% C) having dimen- 
sions of 0.07 x  8.5 x  8.5 cm were prepared using a Pharmacia GSC-8 gel casting apparatus 
and  a  Pharmacia  gradient  maker.  Samples and  the  molecular weight  standards  were 
dissolved in Laemmli sample buffer containing  1 mM dithiothreitol and heated to 90°C 
for  3  min.  Electrophoresis  was  performed  using  the  discontinuous  buffer  system  of 
Laemmli at constant voltage (150 V) for 3 h at 10°C in a Pharmacia GE-4 electrophoresis 
apparatus.  The molecular weight standards  used  to calibrate the gels were as follows: 
phosphorylase b, 94,000; BSA, 67,000; ovalbumin, 43,000; carbonic anhydrase, 30,000; 
soybean trypsin inhibitor, 20, 100; a-lactalbumin, 14,400; and cytochrome c, 12,500. The 
gels were fixed and stained with silver as previously described (24). 
Analytical IEF.  Analytical IEF was performed on 5% T  polyacrylamide gels having a 
thickness  of 0.5  mm and  containing  carrier ampholytes with  a  pH  range of 3.5-9.5 
(UltroPag; LKB). The anolyte was  1 M H3PO4 and the catholyte was  1 M NaOH. The 
gels were run at constant power (25  W) until a  maximum of 2,000  V  was reached,  at 
which point they were run at constant voltage. The runs lasted  1 h and were performed 
at 10 ° C on a Pharmacia FBE-3000 flatbed electrophoresis apparatus. Afterwards, the gels 
were fixed in a solution containing 11.5% trichloroacetic acid/3.4% sulfosalicylic acid for 
1 h and in a solution containing 25% ethanol/8% acetic acid (vol/vol) for 5 rain. The gels 
were then stained with Coomassie Brilliant Blue R250 using standard techniques. Calibra- 
tion of the gels was performed with the following pI standards: lentil lectin: 8.65,  8.45, 
and 8.15 species; horse myoglobin: 7.35 and 6.85 species; human carbonic anhydrase B, 
6.55; bovine carbonic anhydrase B, 5.85; 13-1actoglobulin A, 5.20; soybean trypsin inhibi- 
tor, 4.55; and amyloglucosidase, 3.50. 
Samples of IL-I analyzed by analytical IEF were first concentrated and desalted  by 
ultrafiltration  using a  YM-10  membrane. Aliquots (10  #1) of the  sample and standard 
mixture were then  applied  to  the  surface  of the  gel  with  a  template.  Bioactivity was 
determined after electrophoresis by slicing a  lane into  1.5-mm sections and eluting the 
sections in culture medium containing 10% fetal calf serum at 4 °C for 12 h before assay. 
Bioassays.  IL-1  bioactivity  was  determined  by  its  capacity  to  stimulate  thymocyte SCHMmT  775 
proliferation in the presence of phytohemagglutinin, as previously described (25). Units 
of IL-1  activity were calculated, as previously described (26),  by making reference to 
aliquots of a partially purified preparation of IL-1 that had been arbitrarily assigned an 
activity of 100  U/ml. The dose response lines of the samples and that of the standard 
preparation were parallel and they were compared at 50% of the response given by a 1  :  10 
dilution of the standard preparation. Because thymocyte proliferation may also indicate 
the presence of interleukin 2 (IL-2), crude culture supernatants and purified preparations 
of IL-1 were also tested for IL-2 activity by using a standard microassay (26) based on the 
IL-2-dependent proliferation of a murine T cell line (HT-2). 
Protein Determinations.  During the chromatographic separations, absorbance was mon- 
itored at 210 nm and the integration values obtained by the peak integrator were used to 
determine the amount of protein in a given peak (27).  In those cases where incomplete 
resolution from neighboring peaks prevented accurate integration, the  region of the 
chromatogram corresponding to the active fractions was cut and weighed. The relation- 
ship between paper weight and integration units was determined by performing the same 
operation on well-resolved peaks. The number of integration units shown for the crude 
concentrate (Table II) was obtained by summing all the integratio~a values obtained during 
the isocratic runs on the preparative Synchropak AX300 column, plus all those obtained 
when the column was eluted with a gradient of increasing ionic strength to remove bound 
protein (5-500 mM NaiPO4, pH 7.25).  Integration units were corrected for column flow 
rate (27) and the number of area units obtained during blank runs. 
The following method was used to convert integration units to protein weight. Known 
amounts of bovine serum albumin (BSA) (1-50 #g) were chromatographed on the HPLC 
size exclusion column at a flow rate of 1 ml/min while monitoring absorbance at 210 nm. 
By plotting the number of integration units as a  function of protein  weight, a  linear 
relationship was obtained. The slope of this line (89.1  ×  106 integration U/mg protein) 
was then used to calculate the amount of protein in the crude concentrate (see above) and 
the amount of protein associated with IL-1  activity after each step of the purification 
protocol (Table II). 
For the purpose  of measuring protein concentration in crude  culture supernatants 
(Table II), the Coomassie Brilliant Blue method of Spector (28) was employed using BSA 
as a standard. 
Results 
Thymocyte proliferation  activity was  generated  in  culture  supernatants  by 
stimulating peripheral blood mononuclear cells with purified phytohemaggluti- 
nin for 4 d. Although thymocyte proliferation activity may reflect the presence 
of IL-2 as well as IL-1, IL-2, as specifically measured on HT-2 cells (see Materials 
and Methods), peaked on day 1 and thereafter decreased dramatically. By day 
4,  1% of peak IL-2 activity remained (data not shown). These observations are 
in  agreement  with  previous  studies,  which  have  shown  that  IL-2  is  rapidly 
absorbed in culture by activated T  lymphocytes (29, 30). Thymocyte proliferation 
activity, on the other hand, continued to rise or remained stable from days 1-4. 
It was therefore concluded that the thymocyte proliferation activity found in 4- 
day-old culture supernatants was largely due to IL-1. 
Attempts to obtain a high specific activity of IL-1 by culturing the mononuclear 
cells in the absence of exogenous serum proteins were unsuccessful until the cells 
were cultured at high settled cell density. As shown in Table I, the generation 
of thymocyte proliferation (IL-1) activity was largely serum  dependent in  low 
density cultures (horizontal flasks). Culture in upright vessels nearly eliminated 
the serum  requirement  for  IL-1  generation with a  resultant steep  increase  in 
specific biological activity. The culture supernatants used for the purification of 776  PURIFICATION OF  NORMAL  HUMAN  IL-1 
TABLE  I 
Effect of Culture Conditions on the Generation of Thymocyte 
Proliferation  Activity by Mononuclear Cells* 
Culture orientation  FCS (I %)  Activity  Sp act* 
Vertical 
U/ml  U/rag 
-  54  1,800 
+  59  62 
Horizontal  -  7  233 
+  35  39 
* The results  are  those  of a  representative experiment in which  the 
supernatants from replicate flasks were pooled after 4 d of culture and 
assayed in the thymocyte proliferation assay. 
* Protein was determined by reaction with Coomassie Blue as previously 
described (28). 
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FIGURE  1.  High  performance anion exchange  chromatography  of concentrated culture 
supernatant. 200-#1 aliquots of 1,000-fold concentrated culture supernatant were chromato- 
graphed isocratically on a preparative (250 x  10 ram) Synchropak AX300 column equilibrated 
in 5 mM NaiPO4 buffer, pH 7.25,  at a flow rate of 3 ml per min. The absorbance of the 
effluent at 210 nm is shown in the upper panel. Fractions were collected at 0.5 min intervals 
and assayed for IL-1 activity (U/ml) in the thymocyte proliferation assay (lower panel). The 
hatched  area in the  upper panel represents those  fractions  in consecutive  runs that were 
pooled, concentrated, and further purified. 
IL-1  were consequently prepared in upright flasks in the absence of exogenous 
serum. 
When concentrated culture supernatant was chromatographed isocratically on 
a preparative HPLC  DEAE anion exchange column (Synchropak AX300) equil- 
ibrated in 5  mM  NaiPO4 buffer,  pH  7.25  (Fig.  1),  a  significant portion of the SCHMIDT 
TABLE  II 
Purification  of Normal Human IL-I* 
777 
Total 
Step  activity* in  Total 
units x  protein|  Sp act 
10-~ 
Times  Percent 
purified  yield 
rag  U/mg 
1.  Crude concentrated  406  147  2.7 X 103 
culture supernatant 
2.  Preparative HPLC  146  0.52  2.8 ×  105 
anion exchange 
chromatography 
3.  Analytical HPLC  138  0.021  6.5 X  106 
anion exchange 
chromatography 
4.  HPLC size exclusion  122  0.016  7.6 X 106 
chromatography 
--  100 
102  36 
2,380  34 
2,761  30 
* The results are those of a representative run in which 5,000 ml of crude culture supernatant were 
processed. 
~t Activity was measured in the thymocyte proliferation assay as described in Materials and Methods. 
! Protein was measured by calibrating the peak integrator with known amounts of BSA as described 
in Materials and Methods. 
applied activity (-40%,  Table  II) failed to bind tightly to the column. Similar 
observations  have  been  made  with  conventional  diethyl  aminoethyl (DEAE) 
columns  (11,  17,  31).  In  contrast  to  conventional  DEAE  substituted  resins, 
however, the IL-1  activity was separated from most of the other nonbinding 
proteins as it eluted from the column. Not shown in Fig. 1 is the gradient portion 
of the run, which demonstrated that approximately two-thirds of the total protein 
and 60% of the thymocyte proliferation activity bound tightly to the column and 
could be eluted with a gradient of increasing ionic strength. The bound activity 
was mainly due to the various minor charged species of IL-1  (data not shown) 
and no further attempt at their purification was made. In these studies, the liquid 
chromatograph was programmed to perform 10 consecutive isocratic runs before 
regenerating the column with a  gradient of increasing ionic strength. A highly 
reproducible elution pattern permitted the automated collection of IL-1 contain- 
ing  fractions  in  narrow  bands  (hatched areas  in  Figs.  1  and  2)  without  any 
significant loss of this material or excessive contamination with nearby protein 
peaks. 
The active fractions represented by the hatched area in Fig.  1 were concen- 
trated by ultrafiltration and chromatographed on an analytical AX300 column 
using the same conditions as for the preparative size column, except that  the 
flow rate was reduced to 1 ml/min. This column step was necessary (a) to remove 
the trailing portions of peaks, which eluted in advance of IL-1 on the preparative 
column and (b) to remove late eluting material from previous consecutive runs. 
Fig. 2 shows that, upon chromatography on the analytical AX300 column, the 
IL-1  activity eluted as a  single sharp peak and coincided with a  peak of A210 
absorbing material. SDS-PAGE of the active and flanking fractions showed that 
a ~ 15,000-mol wt band was the dominant species in the most active fraction and 778  PURIFICATION  OF  NORMAL  HUMAN  IL-1 
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FIGURE 2.  Rechromatography  of partially  purified  human  IL-1  on  Synchropak  AX300. 
Partially purified  IL-1  obtained after passage on a  preparative  Synchropak AX300 column 
was concentrated by ultrafiltration and chromatographed isocratically on an analytical (250 x 
4.1 mm) Synchropak AX300 column equilibrated in 5 mM NaiPO4 buffer, pH 7.25, at a flow 
rate of 1 ml/min. The absorbance of the column effluent at 210 nm is shown in the upper 
panel. Fractions were collected at 0.5 min intervals and assayed for IL-I activity (U/ml; lower 
panel).  The  hatched  area  in  the upper  panel  represents  those fractions that  were pooled, 
concentrated, and further purified by high performance size exclusion chromatography. 
that its staining intensity in this and flanking fractions correlated well with the 
amount of IL-1 activity present (data not shown). 
Since the fractions flanking the hatched area in Fig. 2 appeared on SDS-PAGE 
to contain proteins of 25,000 mol wt or greater, the fractions represented by the 
hatched area in Fig. 2 were concentrated by ultrafiltration and chromatographed 
on an HPLC size exclusion column (TSK-G 2000 SW). As shown in Fig. 3, the 
IL-1  activity eluted with a  sharp symmetrical peak of A210 absorbing material. 
The  molecular weight  of this  material,  as  determined by  calibration  of the 
column with known molecular weight standards (Fig. 4, panel B), was ~ 12,000. 
Rechromatography of this material, i.e., the material eluting between 20.5 and 
22.5 min, yielded a single peak when monitored at either 210 or 280 nm (data 
not shown). When the fractions containing thymocyte proliferation activity were 
tested for IL-2 activity, none was found. 
The purity of this  IL-]  preparation  was further demonstrated in  two ways. 
First,  the  four  IL-l-containing  fractions  shown  in  Fig.  3  were  pooled  and 
analyzed by  SDS  gradient  PAGE  under reducing conditions as  described  in 
Materials and Methods. Electrophoresis followed by silver staining revealed only 
a single band (Fig.  5). The molecular weight of this material, as determined by 
calibration of the gel with known molecular weight standards, was 15,000 (Fig. 2O0 
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FIGURE 3.  High performance  size exclusion chromatography  of partially purified  human 
IL-1.  Partially  purified  IL-1  obtained  after  chromatography  on  an  analytical  Synchropak 
AX300 column was chromatographed on a  600  x  7.5 mm TSK-G 2000 SW size exclusion 
column  equilibrated  in  100  mM  NaiPO4,  pH  6.95,  at a  flow rate  of  1  ml per  rain.  The 
absorbance of the column effluent at 210  nm is shown  in the upper panel.  Fractions were 
collected at  0.5  rain  intervals and  assayed  for 1L-I  activity (U/ml; lower panel).  The  four 
fractions shown  in the lower panel (vertical bars) eluted between  20.5  and  22.5  min.  The 
negative deflection at the end of the chromatogram is due to passage of the sample buffer 
through the detector. 
4, left panel). Second, the isolated material was examined by analytical IEF on 
uhrathin polyacrylamide gels. After focusing, adjacent lanes were either stained. 
with  Coomassie  Brilliant  Blue  R-250  or  sliced,  eluted,  and  assayed for  IL-1 
activity. As  shown  in  Fig.  6,  a  single band  having a  pI  of 6.8  was observed. 
Furthermore, this band was coincident with a single sharp peak of IL-1 activity. 
Table II summarizes the purification of the major charged species of human 
IL-1. The results from one representative run are given. The integration values 
obtained by the peak integrator when monitoring absorbance at 210  nm were 
used to determine the amount of protein obtained after each purification step 
(see Materials and Methods). As shown, the protocol results in a  30%  yield of 
activity and approximately a  2,700-fold purification of IL-1. A  specific activity 
of 7.6  x  106 U  per mg protein was calculated (Table II). Most of the losses of 
IL-1  activity resulted from the loss  of minor charged species during the first 
AX300 step. 780  PURIFICATION  OF  NORMAL  HUMAN  IL-1 
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FIGURE 4.  Molecular weight determination of purified human IL-1 by SDS gradient PAGE 
and high performance size exclusion chromatography. The log of the molecular weights of 
standard proteins (see  Materials and Methods) was plotted as a  function of their migration 
distance on SDS gradient PAGE or their elution time on size exclusion chromatography. The 
molecular weight of IL-1  was determined by plotting the observed migration distance and 
elution time (X) of the purified material on the calibration line obtained from the polyacryl- 
amide gel and size exclusion column, respectively. 
FIGURE 5.  SDS  gradient  PAGE of purified human  IL-1. The  active fractions in  Fig.  3 
(elution time 20.5-22.5 min) were pooled and an aliquot was analyzed by SDS gradient PAGE 
as detailed in Materials and Methods. The gel was then fixed and stained with silver. The 
positions of the standard proteins used to calibrate the gel are shown at right. 
Purified  human  IL-1  was  tested  at  various  concentrations  in  the  murine 
thymocyte proliferation assay (Fig. 7). The  concentration of IL-1 was determined 
by measuring absorbance at 210 nm (see Materials and Methods) and the molarity 
was calculated using a  molecular weight of 15,000.  Based on these calculations, SCHM1DT  781 
FIGURE 6.  Analytical IEF of purified human IL-1. After removing an aliquot for analysis on 
SDS gradient PAGE, the remaining isolated material (Fig. 3; elution time 20.5-22.5 min) was 
desalted, concentrated, and applied to two adjacent lanes of an IEF gel (pH 3.5-9.5) by means 
of an applicator template (see Materials and Methods). Proteins of known pI were applied to 
separate lanes in order to calibrate the pH gradient of the gel. After focusing, the lanes bearing 
standard proteins (upper gel slice) and one of the lanes bearing IL-1 (lower gel slice) were 
fixed and stained with  Coomassie Brilliant Blue  R-250 (see  Materials and Methods).  The 
remaining gel slice bearing IL-1 was sliced, eluted, and assayed for IL-1 bioactivity (U/ml). 
The arrow indicates a  staining artifact seen in both the standard protein and IL-l-bearing 
lanes resulting from scoring of the gel surface by the applicator template. 
saturable stimulaton of thymocyte  proliferation was observed with a half-maximal 
stimulation at  10 -1° M  IL-1.  Maximal stimulation was obtained at  10 -8 M and 
detectable activity was still observed at 10 -12 M IL-1. 
Discussion 
The current study describes a rapid, efficient protocol for the purification of 
normal human IL-1.  The success of the protocol was dependent in part on an 
ability to achieve a  high specific activity of IL-1  by culturing the mononuclear 
cells  under  "serum-free" conditions.  As  had  been  reported  by others,  it  was 
initially difficult to produce IL-1 in the absence of serum or exogenous proteins 
(32).  However, by culturing the cells in upright flasks and thereby achieving a 
high settled cell density, this difficulty was circumvented (Table I). Phytohemag- 
glutinin was chosen as an inducing agent because it could be obtained in highly 
purified  form,  was  readily  separated  from  IL-1  on  the  basis  of charge  and 
molecular weight, and because it is known to recruit T  cells that augment the 
production  of IL-1  by  monocyte-macrophages (25,  33).  The  ability  of other 
stimulants (e.g. silica,  lipopolysaccharide) to substitute for purified phytohemag- 
glutinin in this protocol remains to be studied. 
My initial  efforts to purify human  IL-1  involved two different approaches, 1~0 
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FIGURE 7.  Dose  response analysis of purified human IL-1 in the murine thymocyte  prolif- 
eration assay. The  amount of IL-1 protein used in  this experiment was determined by 
measuring absorbance at  210  nm  as described in  Materials and  Methods. Molarity was 
calculated using a molecular weight of 15,000. The points represent the means of triplicate 
determinations. 
neither of which was ultimately satisfactory. The first of these used preparative 
IEF.  This  method  offered  several  advantages  including  high  capacity,  high 
resolution, and sample concentration.  Moreover, since the majority of proteins 
have pI's in the range  of 4  to 6  (34),  sharp  separation  of the pI  6.8 species of 
IL-1  from most of the contaminating  proteins was achieved.  Others have used 
IEF as a  technique  for purifying human  IL-1  on the basis of these advantages 
(13,  18).  However, a major drawback to using IEF for the purification of a small 
protein  such  as  IL-1  is  contamination  of the  sample  with  carrier  ampholytes. 
Although most of these can be removed by simple dialysis, it was impossible to 
completely remove them from IL-1 by a combination of exhaustive dialysis and 
two sequential passages over an HPLC size exclusion column (J. Schmidt and C. 
Oliver,  unpublished  observations).  Despite  manufacturers'  assurances  to  the 
contrary, high  molecular weight species of carrier ampholytes have been docu- 
mented  (35,  36).  Given  the  activity  of carrier  ampholytes  in  some  in  vitro 
biological (14) and biochemical (37) assays, their strong UV absorption, and their 
recognized ability to interfere in most assays used for protein determination (36), 
it was decided to use carrier  ampholytes and  IEF  only as analytical  tools. The 
second  approach  involved  the  use  of reverse  phase  high  performance  liquid 
chromatography  (RPC),  a  technique  that  has  been  highly  successful  in  the 
purification  of other trace mediators such as IL-2 (38),  transformation  growth 
factors  (39),  and  immune  interferon  (40).  Despite  using  a  variety  of buffer 
systems and bonded phases under various conditions of pH and temperature,  it 
was not possible to obtain sufficient recovery of activity to make this approach SCHMIDT  783 
feasible. Nevertheless, preliminary results suggest that RPC may be a  powerful 
tool for the purification of inactive IL-1 for structural analysis. 
The purification protocol presented illustrates the power of anion exchange 
HPLC as a tool for the purification of a  trace, labile lymphokine, such as IL-1. 
Moreover, these results introduce the use of isocratic separations in high per- 
formance anion exchange liquid chromatography as an effective means of sepa- 
rating otherwise poorly resolved protein species. Experience with conventional 
DEAE-substituted  media suggested that anion exchange  chromatography (11, 
17, 31) was not a satisfactory method for the purification of human IL-1 because 
a  large  portion  of the  IL-1  activity  failed  to  bind  to  these  media  and  little 
resolution among nonbinding proteins  was  obtained.  Likewise,  initial  experi- 
ments with a number of different HPLC anion exchange columns showed that a 
significant  portion  of  the  applied  IL-1  activity  did  not  bind.  However,  by 
chromatographing the sample in low ionic strength buffer at a pH slightly above 
the major charged species of IL-1, excellent separation of IL-1 from the majority 
of nonbinding contaminants  was  obtained.  Furthermore,  these  conditions al- 
lowed most contaminating proteins and the minor charged species of IL-1 to be 
removed as a result of tight binding to the column. Subsequent chromatography 
of the partially purified material on an analytical HPLC anion exchange column 
and HPLC size exclusion column was sufficient to yield highly purified material 
as judged by SDS gradient PAGE and analytical IEF. 
This approach to the purification of IL-1 is advantageous because it results in 
the isolation of a  single charged species. Analysis of mixtures of IL-l-charged 
species might be  misleading, since the various species may differ considerably 
with  respect  to  their  biochemical  properties  and  specific  biological  activity. 
Modification of the purification protocol should make it possible to isolate other 
charged species of IL-1  so that their biochemical and biological properties can 
be  compared.  Although  calculations  of yield  may  be  favorably  or  adversely 
influenced by the presence of inhibitors or comitogens in the starting material 
that are subsequently removed during purification, the overall yield of bioactivity 
compares  quite  favorably  with  yields  previously  reported  by  others  for  the 
purification of murine IL-1 (12) and the partial purification of human IL-1 (13, 
17-19).  Small  differences  in  specific  activity  were  observed  (4-10%)  for  the 
purified material  but are  attributed  to imprecision encountered in  measuring 
IL-1 activity in the thymocyte proliferation assay. In the thymocyte proliferation 
assay, IL-1 exhibited saturable stimulation at a concentration of 10 -8 M and half- 
maximal stimulation at a  concentration of 10  -t° M.  These data are consistent 
with those recently reported for purified murine IL-1 (12) and suggest that IL- 
l  action is mediated by saturable, high affinity receptors. 
Partial  biochemical characterization  of purified  IL-1  showed that  it  has  an 
isoelectric point of 6.8, in good agreement with values obtained previously by 
preparative  focusing  techniques  (10,  11,  13).  The  molecular  weight  of  the 
material, as determined by SDS-PAGE, is 15,000, also in agreement with values 
obtained previously by conventional gel filtration chromatography on Sephadex 
(17,  31). The somewhat lower value obtained by HPLC size exclusion chroma- 
tography  is  most  likely  due  to  a  weak  interaction  with  the  column  packing 
material. This is based on the observations (a) that IL-1 is retarded on this type 784  PURIFICATION OF  NORMAL HUMAN IL-1 
of size exclusion media as compared to  Sephacryl (11),  and (b)  that  ethylene 
glycol is required to obtain good recoveries and to prevent band broadening on 
TSK-G 3000 SW preparative size exclusion columns (unpublished observations). 
Because the elution time observed for the high pI species of IL-1  on each of 
the three HPLC columns was highly reproducible, chromatography was readily 
automated. Furthermore, the speed of HPLC separations now make it possible 
to prepare microgram quantities of IL-1 on a regular basis (15-30 gg/wk). This 
amount,  though small  by conventional protein  chemistry standards,  has been 
shown  to  be  adequate  for  receptor  binding  studies  (41)  and  many  protein 
analytical techniques including amino acid analysis (42),  peptide analysis (43), 
and sequence analysis (44). Thus, it should now be possible to study the compo- 
sition of human IL-1 in detail, compare it to IL-1 or IL-l-like molecules derived 
from other sources, such as keratinocytes (45), and initiate studies designed to 
identify receptor sites for IL-1  on a variety of lymphoid and nonlymphoid cells 
and  tissues.  Moreover,  because  the  material  was  purified without  the  use  of 
phorbol esters or carrier ampholytes, this material should prove useful in con- 
firming the various bioactivities ascribed to IL-1. 
Summary 
A protocol for the rapid, efficient purification of the major charged species of 
human interleukin  1 (IL-1) has been developed using high performance anion 
exchange and size exclusion chromatography. The isolated material is pure as 
determined by sodium dodecyl sulfate (SDS) gradient polyacrylamide gel electro- 
phoresis (PAGE) and analytical isoelectric focusing (IEF). The molecular weight 
of the purified material is 15,000 and the isoelectric point (pI) is 6.8, values that 
are in good agreement with those previously reported for human IL-1.  10 -1° M 
concentrations of the  purified  material  give  half-maximal stimulation  in  the 
thymocyte proliferation assay. Amounts of IL-1  sufficient for receptor studies 
and detailed biochemical analysis can now be produced on a regular basis. 
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